ResultsIQ

ResultsIQ › Latest results › India Glycols Limited

India Glycols Limited strategy deck summary

NSE: INDIAGLYCO · BSE: 500201

Strategy deck of 2 Sep 2026, summarised by AI from the filing.

India Glycols demerged into three independently listed companies effective 1 September 2026, targeting ₹2,000 cr net revenue and ₹400 cr EBITDA in 4–5 years.

Key takeaways

  1. Demerger IGL demerged into three independently listed companies effective 1 September 2026, with IGL retaining Bio-based Specialty Materials, Sustainable & Performance Chemicals and Gases.
  2. Guidance Management aspires to ₹2,000 cr net revenue and ₹400 cr EBITDA in the next 4–5 years.
  3. Change The demerger creates three focused, independently listed businesses with separate strategies and capital allocation.
  4. Driver Growth is driven by application-led specialty chemistries, the bio-based materials platform and expansion in high-value global markets.
  5. Risk Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.

Original filing on BSE

India Glycols Limited Q1 FY27 results

As filed: Revenue ₹2,988 cr (+19% year on year), EBITDA ₹170 cr (+13% year on year), PAT ₹96.8 cr (+33% year on year), EBITDA margin 5.7% (−32 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,360 cr (+8% year on year), EBITDA ₹167 cr (+14% year on year), PAT ₹86.9 cr (+36% year on year), EBITDA margin 7.1% (+39 bps). Score 40 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was above it. EBITDA margin rose 39 bps year on year. Revenue fell 7% from last quarter. Share price after the results: −9.0% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹2,551 cr (+5% year on year), EBITDA ₹175 cr (+43% year on year), PAT ₹67.6 cr (+19% year on year), EBITDA margin 6.9% (+180 bps). Score 55 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 180 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹127 cr on a year ago, against ₹305 cr the year before. Share price after the results: −11.1% in 30 days (Nifty 500: −7.8%).
  • Q2 FY26: Revenue ₹2,412 cr (+13% year on year), EBITDA ₹157 cr (+34% year on year), PAT ₹65.0 cr (+30% year on year), EBITDA margin 6.5% (+105 bps). Score 64 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 105 bps year on year. Revenue fell 4% from last quarter. Revenue rose ₹268 cr on a year ago, against ₹274 cr the year before. Share price after the results: +2.7% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹2,503 cr (+10% year on year), EBITDA ₹150 cr (+19% year on year), PAT ₹73.0 cr (+22% year on year), EBITDA margin 6.0% (+47 bps). Score 48 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 47 bps year on year. Revenue rose ₹220 cr on a year ago, against ₹389 cr the year before.
  • Q4 FY25: Revenue ₹2,189 cr (+7% year on year), EBITDA ₹146 cr (+39% year on year), PAT ₹64.0 cr (+52% year on year), EBITDA margin 6.7% (+152 bps). Score 60 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 152 bps year on year. Revenue fell 10% from last quarter. Revenue rose ₹150 cr on a year ago, against ₹423 cr the year before. Share price after the results: +7.6% in 28 days (Nifty 500: +0.2%).
  • Q3 FY25: Revenue ₹2,424 cr (+14% year on year), EBITDA ₹123 cr (+22% year on year), PAT ₹57.0 cr (+36% year on year), EBITDA margin 5.1% (+31 bps). Score 49 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was well above it. EBITDA margin rose 31 bps year on year. Revenue rose ₹305 cr on a year ago, against ₹595 cr the year before.
  • Q2 FY25: Revenue ₹2,144 cr (+15% year on year), EBITDA ₹117 cr (+23% year on year), PAT ₹50.0 cr (+32% year on year), EBITDA margin 5.5% (+38 bps). Score 65 of 100, In line with trend. EBITDA margin rose 38 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 6% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

India Glycols Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.